Company Filing History:
Years Active: 2023
Title: Inbar Friedrich Ben Nun: Innovator in Nuclear Reprogramming
Introduction
Inbar Friedrich Ben Nun is a prominent inventor based in Rockville, MD (US). She has made significant contributions to the field of cellular reprogramming, particularly through her innovative methods that utilize synthetic transcription factors. Her work has the potential to revolutionize stem cell therapy and its applications in treating various diseases.
Latest Patents
Inbar holds a patent titled "Methods for nuclear reprogramming using synthetic transcription factors." This patent outlines methods for reprogramming mammalian somatic cells by regulating the expression of endogenous cellular genes. The techniques described in her patent enable the activation of embryonic stem cell-associated genes, such as oct3/4, while suppressing somatic cell-specific and cell death-associated genes. By modulating the endogenous transcription machinery with synthetic transcription factors, her methods allow for faster and more efficient nuclear reprogramming, which is crucial for clinical and commercial applications. The patent also includes therapeutic methods for using cells obtained through these techniques for the treatment of diseases amenable to stem cell therapy, along with kits designed for such uses.
Career Highlights
Inbar is currently employed at Lonza Walkersville, Inc., where she continues to advance her research in cellular reprogramming. Her innovative work has garnered attention in the scientific community, and she is recognized for her contributions to the field.
Collaborations
Inbar has collaborated with notable colleagues, including Eytan Abraham and Thomas Payne. These collaborations have further enhanced her research and development efforts in the area of synthetic transcription factors and cellular reprogramming.
Conclusion
Inbar Friedrich Ben Nun is a trailblazer in the field of nuclear reprogramming, with her innovative methods paving the way for advancements in stem cell therapy. Her contributions are poised to have a lasting impact on medical science and therapeutic applications.